Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
Natera announced results from a study published in JAMA Dermatology showing its Signatera test outperformed the standard AMERK test in predicting Merkel Cell Carcinoma recurrence. In the 169-patient study, Signatera demonstrated superior sensitivity (90% vs 55%) and detected relapse earlier, with a median lead time of 5.1 months compared to 2.1 months for AMERK.
Key figures
- P value
- < 0.001
- Patient count
- 169
- Sensitivity amerk
- 55%
- Sensitivity signatera
- 90%
- Lead time amerk months
- 2.1
- Hazard ratio difference
- 6.6
- Lead time signatera months
- 5.1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.